What are the main challenges in daily care for a child with SMA, particularly concerning feeding and breathing?

Daily care often focuses on managing muscle weakness, especially for breathing and feeding. Children may require respiratory support, such as non-invasive ventilation, and careful monitoring for respiratory infections. Feeding difficulties can lead to poor growth and aspiration risk, often necessitating specialized feeding techniques or even a feeding tube. Physical therapy, occupational therapy, and assistive devices are vital for maintaining mobility, preventing contractures, and supporting daily activities.

Is spinal muscular atrophy an inherited condition, and what does that mean for family planning?

Yes, SMA is an autosomal recessive genetic disorder, meaning a child must inherit two copies of a mutated gene (one from each parent) to develop the condition. Parents who are carriers typically do not have symptoms themselves. For carrier parents, there is a 25% chance with each pregnancy that their child will inherit two mutated copies and develop SMA. Genetic counseling is highly recommended for affected families or those with a family history to understand inheritance patterns and reproductive options.

What are the key early warning signs of spinal muscular atrophy (SMA) that parents should look for in an infant or young child?

Early signs vary by type but commonly include profound muscle weakness and floppiness (hypotonia), often noticed as poor head control or difficulty reaching developmental milestones like sitting or crawling. Infants may have weak cries, feeding difficulties, and a bell-shaped chest due to weak respiratory muscles. For the most severe forms, reduced fetal movement might be noted before birth, and infants may be born with joint contractures.

How is spinal muscular atrophy diagnosed, and what is the significance of early diagnosis?

SMA is primarily diagnosed through genetic testing, which identifies mutations in the SMN1 gene. Early diagnosis is crucial because several disease-modifying treatments are now available that can significantly slow disease progression and improve motor function, especially when started before symptoms become severe or irreversible. Newborn screening programs are increasingly being implemented to allow for the earliest possible intervention.

Spinal muscular atrophy

Spinal muscular atrophy (SMA) is a genetic disorder that causes progressive weakness and wasting of skeletal muscles due to loss of motor neurons, with severity ranging from fatal infantile forms to mild adult‑onset disease.

Overview

Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting of muscles used for movement (skeletal muscles). It is caused by loss of specialized nerve cells, called motor neurons, that control muscle movement. Weakness is typically more severe in muscles close to the body’s center (proximal) than in distal muscles, and it usually worsens with age.

Several types of SMA are caused by mutations in the same genes, differing in age of onset and severity, though there is overlap. Related motor‑neuron diseases (e.g., SMA with progressive myoclonic epilepsy, SMA with lower‑extremity predominance, X‑linked infantile SMA, and SMA with respiratory distress type 1) are caused by mutations in other genes.

Types

Type 0 (Prenatal onset)

Evidence of disease is present before birth; it is the rarest and most severe form. Affected infants move less in utero, often are born with joint contractures, have extremely low muscle tone (hypotonia), and very weak respiratory muscles. Most do not survive past infancy due to respiratory failure; some also have congenital heart defects.

Type I (Werdnig‑Hoffmann disease)

The most common and severe form, with muscle weakness evident at birth or within the first few months. Affected children cannot control head movements or sit unassisted, may have swallowing difficulties, poor growth, and breathing problems caused by weak respiratory muscles and a bell‑shaped chest. Most do not survive past early childhood because of respiratory failure.

Type II (Dubowitz disease)

Weakness develops between 6 and 12 months of age. Children can sit without support but may need help to get to a seated position; they cannot stand or walk unaided. Common features include finger tremors, a side‑to‑side spinal curvature (scoliosis), and potentially life‑threatening respiratory muscle weakness. Life expectancy varies, with many individuals living into their 20s or 30s.

Type III (Kugelberg‑Welander disease)

Onset occurs after early childhood. Individuals can stand and walk unaided initially, but walking and stair climbing become increasingly difficult over time. Many later require a wheelchair. Life expectancy is typically normal.

Type IV

Rare, usually beginning in early adulthood. Affected individuals experience mild‑to‑moderate muscle weakness, tremors, and mild breathing problems. Life expectancy is normal.

Frequency

Spinal muscular atrophy affects approximately 1 per 8,000 to 10,000 people worldwide. Type I accounts for about half of all cases; types II and III are the next most common, while types 0 and IV are rare.

Causes

Mutations in the SMN1 gene cause all SMA types described above. The number of copies of the SMN2 gene modifies disease severity and influences which type develops.

Both SMN1 and SMN2 provide instructions for making the survival motor neuron (SMN) protein. Normally, most functional SMN protein is produced from SMN1, with a smaller amount from SMN2. The SMN protein is part of the SMN complex, essential for maintenance of motor neurons. Motor neurons transmit signals that cause skeletal muscles to contract.

Most individuals with SMA lack a portion of the SMN1 gene, reducing SMN protein production. This shortage leads to motor‑neuron death, loss of signal transmission, and subsequent muscle weakness and atrophy.

Typical genomic configuration includes two copies of SMN1 and one to two copies of SMN2 per cell, though SMN2 copy number can range up to eight. Higher SMN2 copy numbers are generally associated with milder disease that manifests later. For example, type 0 patients usually have one SMN2 copy, type I have one or two, type II three, type III three or four, and type IV four or more. Additional, largely unknown factors also influence severity.

Genes associated with SMA

SMN1
SMN2

Inheritance

SMA is inherited in an autosomal recessive pattern: both copies of the SMN1 gene in each cell carry mutations. Typically, each parent is a carrier of one mutated copy and shows no symptoms. In rare cases, a child inherits one mutated copy from a parent and acquires a new mutation in the other copy during gamete formation or early embryonic development, meaning only one parent is a carrier.

Extra copies of SMN2 usually arise from random DNA replication errors in an egg or sperm cell or shortly after fertilization; they are not typically inherited from a parent.

Other Names for This Condition

5q SMA
Proximal SMA
SMA
SMA‑associated SMA
Spinal amyotrophies
Spinal amyotrophy
Spinal muscle degeneration
Spinal muscle wasting

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Spinal muscular atrophy, type IV
Genetic Testing Registry: Kugelberg‑Welander disease
Genetic Testing Registry: Spinal muscular atrophy, type II
Genetic Testing Registry: Werdnig‑Hoffmann disease

Genetic and Rare Diseases Information Center

Proximal spinal muscular atrophy type 1
Proximal spinal muscular atrophy type 2
Proximal spinal muscular atrophy type 3
Spinal muscular atrophy

Patient Support and Advocacy

National Organization for Rare Disorders (NORD)

Clinical Trials

ClinicalTrials.gov

Catalog of Genes and Diseases (OMIM)

SPINAL MUSCULAR ATROPHY, TYPE I; SMA1
SPINAL MUSCULAR ATROPHY, TYPE II; SMA2
SPINAL MUSCULAR ATROPHY, TYPE III; SMA3
SPINAL MUSCULAR ATROPHY, TYPE IV; SMA4

Scientific Articles (PubMed)

PubMed

References

Farrar MA, Kiernan MC. The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics. 2015 Apr;12(2):290-302. doi:10.1007/s13311-014-0314-x.
Fuller HR, Gillingwater TH, Wishart TM. Commonality amid diversity: Multi‑study proteomic identification of conserved disease mechanisms in spinal muscular atrophy. Neuromuscul Disord. 2016 Sep;26(9):560-9. doi:10.1016/j.nmd.2016.06.004.
Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015 Nov;33(4):831-46. doi:10.1016/j.ncl.2015.07.004.
Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008 Jun 21;371(9630):2120-33. doi:10.1016/S0140-6736(08)60921-6.
Prior TW, Leach ME, Finanger EL. Spinal Muscular Atrophy. 2000 Feb 24 [updated 2026 Feb 12]. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993‑2026.
Prior TW, Nagan N. Spinal Muscular Atrophy: Overview of Molecular Diagnostic Approaches. Curr Protoc Hum Genet. 2016 Jan 1;88:9.27.1‑9.27.13. doi:10.1002/0471142905.hg0927s88.
Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A. 2004 Oct 15;130A(3):307-10. doi:10.1002/ajmg.a.30251.
Wirth B, Brichta L, Schrank B, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006 May;119(4):422-8. doi:10.1007/s00439-006-0156-7.